The Cystic Fibrosis Foundation is providing additional funding to Arcturus Therapeutics to develop an inhaled messenger RNA therapy for CF that provides lung cells with the correct instructions to make functional cystic fibrosis transmembrane conductance regulator protein. The funding brings our total commitment to Arcturus to approximately $25 million.
Breadth of expertise in business, philanthropy, community engagement, and venture capital to help advance Foundation’s mission
Nosis Bio, an inaugural winner of the Foundation’s Golden Ticket Competition, receives funding to further explore design of novel ligands, which are specialized molecules that could help more precise targeting of relevant cells in the lung.
Centering the patient experience is the only way to successfully reform pharmacy benefit manager practices
Groups urging need for revitalizing antimicrobial development call for passage of the bill this year
Proposed policies would impose significant barriers and add burden for people with CF